Ergometrine (Maleate) is a derivative of ergot (fungus). It produces contraction of uterine muscle and used after delivery of baby to prevent or reduce maternal haemorrhage.
22 Obstetrics and gynecological preparations 22.1 Labor inducers/inhibitors 22.1.1 Oxytocics
Ergometrine (Maleate) also known as Ergobasine Maleate, Ergobasine Maleate, Ergobasine Maleate, Ergobasine Maleate, Ergobasine Maleate, Ergobasine Maleate, Ergobasine Maleate. . It is of Natural origin and belongs to Ergot Alkaloid. It belongs to Alpha adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Analgesics and Anti-inflammatory Agents and Anxiolytics pharmacological group.The Molecular Weight of Ergometrine (Maleate) is 441.50. Its pKa is 6.73 ± 0.16.
Oral absorption of Ergometrine (Maleate) is found to be 97% ±2. Volume of distribution is found to be 73.4 ± 22 litre . Presystemic metabolism is noted to be 72.5% ±2.5 and metabolism is reported hepatic. Plasma half life is 0.5 hr.
Ergometrine (Maleate) is known to interact with other drugs, the details of drug interactions is as follows:
Drug Details Severity Onset Management Adrenaline Coadministration increases blood pressure by vasoconstriction due to alpha adrenergic agonist activity of ergot alkaloids. Moderate Coadministration is not recommended. If use then close clinical monitoring of response, tolerance and excessive vasoconstriction is recommended. Ephedrine Both agents acts additively and synergistically to produce vasoconstriction results in increased blood pressure. Moderate Concomitant use is considered contraindicated. Closely monitor for response and tolerance of patient.
Erythromycin Coadministration increases concentration of ergotamine in the plasma causing untoward peripheral vasoconstriction Moderate Coadministration is not recommended. If use then close clinical monitoring of response, tolerance and excessive vasoconstriction is recommended. Halothane Halothane decreases the oxytcic effects of ergonovine. Minor Closely monitor for change in efficacy during coadministration. Ketamine (HCl) Mifepristone Oral contraceptive increase platelet aggregability and promote thrombus formation Moderate simultaneous use of ergometrine with oral contraceptives should be avoided Oxprenolol (HCl) simultaneous use of ergometrine and b- adrenoceptor blocker may increase peripheral vascular resistance. increase risk of vascular occlusion
. simultaneous use of ergometrine and b- adrenoceptor blocker should be avoided Oxytocin
These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interference in Pathology
No data regarding the pathological interferences produced by Ergometrine (Maleate) is available.
The severe or irreversible adverse effects of Ergometrine (Maleate), which give rise to further complications include Vascular complications, Ischemia, Gangrene.
Ergometrine (Maleate) produces potentially life-threatening effects which include Coma, Seizures, Nausea, Vomiting, Hypertension, Hypotension, Diarrhea, Cold extremities, Severe thirst, Confusion. which are responsible for the discontinuation of Ergometrine (Maleate) therapy.
The signs and symptoms that are produced after the acute overdosage of Ergometrine (Maleate) include Nausea, Vomiting, Seizures, Angina, Confusion, Unconsciousness, Palpitations, Dizziness, Hypertension, Gangrene, Dyspnea, Vasoconstriction of the extremities.
The symptomatic adverse reactions produced by Ergometrine (Maleate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Palpitation, Tinnitus, Abdominal pain, VertigoX, Chest pain, Angina, Shortening of breath, Pulmonary edema, dizziness.
Click on the appropriate strength of the dosage form to view its available brands.
Tabs: 2 mg,
Ergometrine (Maleate)'s dosage details are as follows:
200 mcg 200 (200) 4 hourly IM This amount is given in emergencies such as uterine bleeding. Frequency may be increased from 2 to 4 hourly as needed, for maximum 5 doses. Or Single dose of 250 to 500 mcg can also be given. 200 mcg 200 (200) As recommended. IM A usual dose of Ergometrine (Maleate) alone for prevention or treatment of postpartum or postabortal haemorrhage. 500 µg 500 (500) As recommended. IM Active managment of 3rd stage of labour 200 to 400 mcg 300 (300) 6 hourly PO For parental treatment of haemorrhage. The dose can be given for upto 7 days, untill the danger of atony or haemorrhage has passed. Ergonovine should be swallowed or placed under tongue.
500 mcg 500 (500) 8 hourly PO For the treatment of mild secondary postmartum haemorrhage. The dose can be given for 2 to 7 days.
Paedriatic Dosage ( 20 Kg. )
Not Recommended in this Age Group
Neonatal Dosage ( 3 Kg. )
Not recommended in this age group
High Risk Groups
Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, Geriatrics, and Neonates.
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Warning / Precautions
Ergometrine should not be used for the induction of labor or during the first stage of labor. Its use should be avoided in patients with eclampsia. In case of any kind of infection or illness check with your doctor before taking Ergonovine since sensitivity to ergonovine's effects may increase.It should be used with caution in patient with impaired pulmonary function, sepsis, renal or hepatic disease and in patients with porphyria. Patient should be advised not to drive or use machines while receiving ergonovine.
In case of any kind of infection or illness check with your doctor before taking Ergonovine since sensitivity to ergonovine's effects may increase.
Store in a well closed container. Refrigeration is recommended. Protect from Sunlight.
powered by Disqus. comments powered by